Sucampo Receives Marketing Authorization For Amitiza(R) In Switzerland For Treatment Of Chronic Idiopathic Constipation

Sucampo Pharma Europe Ltd., a subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a marketing authorization for Amitiza® (lubiprostone) 24 microgram (mcg) gel capsules for the long-term treatment of patients with chronic idiopathic constipation (CIC). (Source: GastroIntestinal News From Medical News Today) Go to Source

People who read this also read

• Amitiza(R) For Treatment Of Chronic Idiopathic Constipation
  Sucampo Pharma Europe Ltd., a subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a marketing authorization for Amitiza® (lubiprostone) 24 microgram (mcg) gel capsules for the long-term treatment of patient...
• Human Genome Sciences Announces Submission Of Marketing Authorization Application To EMEA For JOULFERON(R) (ZALBIN™)
  Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that Novartis has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN™) for the treatment of chronic hepatitis...
• Sanofi-aventis: Multaq(R) Approved In The European Union For Patients With Atrial Fibrillation
  Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the European Commission has granted marketing authorization for Multaq(R) (dronedarone 400mg Tablets) in all 27 European member states. This approval follows the European Commission positive opinion issued on September 25, 2009 by the Comm...
• ChemGenex’s Marketing Authorization Application For Omacetaxine Mepesuccinate Validated By The European Medicines Agency
  ChemGenex Pharmaceuticals Limited (ASX:CXS) announced that the European Medicines Agency ("EMEA") has determined that the Marketing Authorization Application ("MAA") for omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and...
• Ipsen’s Decapeptyl(R) 6-Month Formulation Receives Marketing Authorization For The Treatment Of Locally Advanced Or Metastatic Prostate Cancer
  Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical Group announces that the French regulatory authorities (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS) have granted the marketing authorization to the 6-month sustained-release formulation of Decapept...